Loading financial data...

ASTRAZENECA PLC (AZN) SEC Filings | Global Financial Data

ASTRAZENECA PLC

AZNSEC EDGAR

Pharmaceutical Preparations(X0)CIK: 901832

6-K

NOTICE OF AGM

Filed: Mar 10, 2026 | Report: Mar 10, 2026

View on SEC

6-K

FORM 6-K

Filed: Mar 10, 2026 | Report: Mar 10, 2026

View on SEC

6-K

DIRECTOR/PDMR SHAREHOLDING

Filed: Mar 6, 2026 | Report: Mar 6, 2026

View on SEC

6-K

DIRECTOR/PDMR SHAREHOLDING

Filed: Mar 6, 2026 | Report: Mar 6, 2026

View on SEC

6-K

DIRECTOR/PDMR SHAREHOLDING

Filed: Mar 6, 2026 | Report: Mar 6, 2026

Filed: Mar 2, 2026 | Report: Mar 2, 2026

View on SEC

6-K

TOTAL VOTING RIGHTS

Filed: Mar 2, 2026 | Report: Mar 2, 2026

ASTRAZENECA PRICES A $2BN BOND OFFERING

Filed: Feb 26, 2026 | Report: Feb 26, 2026

FILING OF FORM 20-F WITH SEC

Filed: Feb 25, 2026 | Report: Feb 25, 2026

Filed: Feb 24, 2026 | Report: Dec 31, 2025

View on SEC

6-K

FORM 6-K

Filed: Feb 24, 2026 | Report: Feb 24, 2026

View on SEC

6-K

ANNUAL FINANCIAL REPORT

Filed: Feb 24, 2026 | Report: Feb 24, 2026

View on SEC

6-K

DIRECTORATE CHANGE

Filed: Feb 24, 2026 | Report: Feb 24, 2026

View on SEC

6-K

FIXED-DURATION CALQUENCE COMBO APPROVED IN US

Filed: Feb 20, 2026 | Report: Feb 20, 2026

View on SEC

6-K

FINAL RESULTS

Filed: Feb 10, 2026 | Report: Feb 10, 2026

UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION

Filed: Feb 3, 2026 | Report: Feb 3, 2026

Filed: Feb 2, 2026 | Report: Feb 2, 2026

View on SEC

6-K

IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER

Filed: Feb 2, 2026 | Report: Feb 2, 2026

View on SEC

6-K

ASTRAZENECA BEGINS TRADING ON NYSE

Filed: Feb 2, 2026 | Report: Feb 2, 2026

ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC

Filed: Jan 30, 2026 | Report: Jan 30, 2026

View on SEC

6-K

ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030

Filed: Jan 29, 2026 | Report: Jan 29, 2026

ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE

Filed: Jan 20, 2026 | Report: Jan 20, 2026

View on SEC

6-K

AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON

Filed: Jan 8, 2026 | Report: Jan 8, 2026

View on SEC

6-K

TOTAL VOTING RIGHTS

Filed: Jan 2, 2026 | Report: Jan 2, 2026

View on SEC

6-K

DIRECTOR/PDMR SHAREHOLDING

Filed: Dec 22, 2025 | Report: Dec 22, 2025

View on SEC

6-K

ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC

Filed: Dec 22, 2025 | Report: Dec 22, 2025

View on SEC

6-K

UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB

Filed: Dec 22, 2025 | Report: Dec 22, 2025

View on SEC

6-K

DIRECTOR/PDMR SHAREHOLDING

Filed: Dec 19, 2025 | Report: Dec 19, 2025

View on SEC

6-K

SUBCUTANEOUS SAPHNELO APPROVED IN EU

Filed: Dec 16, 2025 | Report: Dec 16, 2025

View on SEC

6-K

ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC

Filed: Dec 16, 2025 | Report: Dec 16, 2025

View on SEC

6-K

HOLDING(S) IN COMPANY

Filed: Dec 4, 2025 | Report: Dec 4, 2025

View on SEC

6-K

BLOCK LISTING INTERIM REVIEW

Filed: Dec 1, 2025 | Report: Dec 1, 2025

View on SEC

6-K

TOTAL VOTING RIGHTS

Filed: Dec 1, 2025 | Report: Dec 1, 2025

View on SEC

6-K

IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER

Filed: Nov 26, 2025 | Report: Nov 26, 2025

View on SEC

6-K

ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND

Filed: Nov 24, 2025 | Report: Nov 24, 2025

View on SEC

6-K

KOSELUGO (SELUMETINIB) APPROVED IN THE US

Filed: Nov 20, 2025 | Report: Nov 20, 2025

View on SEC

Build with this data

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)

Get API Key (Free)